Patent intelligence · US
US 2018326059
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
Patent details — US 2018326059
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 15, 2018
- Expiration
- Nov 10, 2038
- Applicant
- GANYMED PHARMACEUTICALS AG [DE]
- CPC classes
- A61K 31/ 282 A I, A61K 31/ 337 A I, A61K 31/ 513 A I, A61K 31/ 519 A I
Quick answer
US 2018326059 (COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER) is held by GANYMED PHARMACEUTICALS AG [DE]. Status: granted. Granted Nov 15, 2018. Expires Nov 10, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GANYMED PHARMACEUTICALS AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 282 A I, A61K 31/ 337 A I, A61K 31/ 513 A I, A61K 31/ 519 A I, A61K 31/ 675 A I, A61K 31/ 704 A I
More from GANYMED PHARMACEUTICALS AG [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 2018326059?
US 2018326059 (COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER) is held by GANYMED PHARMACEUTICALS AG [DE]. Status: granted. Granted Nov 15, 2018. Expires Nov 10, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2018326059?
GANYMED PHARMACEUTICALS AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2018326059 expire?
Our index shows an expiration date of Nov 10, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.